Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.30
-0.4800-3.25%
Post-market: 14.350.0500+0.35%19:30 EDT
Volume:969.16K
Turnover:14.04M
Market Cap:1.22B
PE:-8.19
High:15.00
Open:14.80
Low:14.17
Close:14.78
52wk High:25.77
52wk Low:4.52
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.07
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.50
PE(LYR):-30.75

Loading ...

Monte Rosa Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
Mar 16

Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Pros

Reuters
·
Mar 16

BUZZ-U.S. STOCKS ON THE MOVE-Sable Offshore, Nebius, Upstart

Reuters
·
Mar 16

BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer

Reuters
·
Mar 16

Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026

Reuters
·
Mar 16

Monte Rosa Therapeutics Inc - to Conduct and Sponsor Trial; Johnson & Johnson to Supply Erleada

THOMSON REUTERS
·
Mar 16

Monte Rosa Therapeutics Inc - to Initiate Phase 2 Study of Mrt-2359 With Apalutamide in Q3 2026

THOMSON REUTERS
·
Mar 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Common Shares

Reuters
·
Mar 05

Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn Disposes of Common Shares

Reuters
·
Mar 03

Monte Rosa Therapeutics Publishes Corporate Presentation on Molecular Glue Degraders and Targeted Protein Degradation Pipeline

Reuters
·
Feb 26

Monte Rosa Therapeutics (GLUE) Receives a Buy from Wedbush

TIPRANKS
·
Feb 25

TD Cowen Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Feb 25

Monte Rosa Therapeutics Chief Medical Officer Filip Janku Disposes of Common Shares

Reuters
·
Feb 25

Monte Rosa announces clinical data from Phase 1/2 study of MRT-2359

TIPRANKS
·
Feb 24

Monte Rosa to Launch Phase 2 Trial of MRT-2359 Plus AR Inhibitor in AR-Mutant mCRPC in Q3 2026

Reuters
·
Feb 24

Monte Rosa Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 23